anti-Chromosome 2 Open Reading Frame 40 (C2orf40) Antibodies

Human Chromosome 2 Open Reading Frame 40 (C2orf40) interaction partners

1. we have provided evidence to show that Ecrg4 is constitutively expressed in atria and the conduction systems and is down-regulated in AF.

2. mutations in Pakistani patients with dilated cardiomyopathy rs375563861 (C2orf40), rs143187236 (MYOM3), and rs564181443 (RTKN2) have 3 fold or higher allele frequency in South Asians than in the global populations

3. ECRG4 down-regulates UBE2C expression in esophageal squamous cell carcinoma cells.

4. Results from many studies support the discovery that ECRG4 plays a critical role in the pathogenesis of atrial fibrillation. [review]

5. UBR5 directly binds to the tumor suppressor esophageal cancer-related gene 4, increasing its ubiquitination to reducing the protein stability of ECRG4 to promote colorectal cancer progression.

6. positive and negative regulatory elements controlling ECRG4 expression include a counter regulation between promoter methylation and Sp1 activation.

7. the overexpression of Beclin 1 promoted apoptosis and decreased invasion by upregulating the expression of ECRG4 in A549 lung adenocarcinoma cells. Therefore, the selection of Beclin l as a target for gene therapy represents a more effective method for the treatment of lung cancer.

8. Downregulated ECRG4 is correlated with lymph node metastasis in nasopharyngeal carcinoma

9. The overexpression of ECRG4 inhibited tumorigenesis.

10. ECRG4 may be a tumor suppressor in renal cancer and serve as a prognostic marker

11. low expression or no expression of ECRG4 in esophageal cancer tissues was closely related to the degree of tumor invasion level, TNM staging, lymph node metastasis and recurrence and survival after surgery.

12. loss of ECRG4 protein expression may be involved in tumor progression and may serve as a prognostic biomarker for breast cancer.

13. Overexpression of ECRG4 inhibited laryngeal cancer cell proliferation and induced cancer cell apoptosis.

14. Our data suggest that methylation-mediated suppression of the ECRG4 gene occurs frequently in nasopharyngeal carcinoma

15. Results identify Ecrg4 as a paracrine factor that activates microglia and is chemotactic for monocytes, with potential as an antitumor therapeutic.

16. ECRG4 is present on the surface of human monocytes and granulocytes and its interaction with the innate immunity receptor complex supports a role for cell surface activation of ECRG4 during inflammation

17. The expression of ECRG4 is frequently upregulated in a papillary thyroid carcinoma through the demethylation mechanism of CpG islands in the gene promoter region, and the ECRG4 has a tumor-promoting function through inducing the cell cycle transition

18. ECRG4 is a candidate tumor suppressor gene that might be involved in the proliferation of esophageal squamous cell carcinoma

19. results suggest that C2ORF40 acts as a tumor suppressor gene in breast cancer pathogenesis and progression and is a candidate prognostic marker for this disease

20. overexpression of ECRG4 enhanced the chemosensitivity of gastric cancer SGC-7901 cells to 5-FU through induction of apoptosis.

Mouse (Murine) Chromosome 2 Open Reading Frame 40 (C2orf40) interaction partners

1. a wound termination factor during wound resolution after cutaneous injury

2. proteolytic cleavage by furin is a posttranslational requirement for proaugurin to suppress cell proliferation

3. identified esophageal cancer-related gene 4 (Ecrg4) as a senescence inducer with implications for the senescence-like state of postmitotic cells in the aging brain.

4. ECRG4 level in differentiated chondrocytes is decreased during hypertrophic maturation